3. Results (continued)

Gene Expression Signatures Associated with In Vivo Response

- Analysis of divergent responses observed within the BCP-ALL subtype to birinapant and the within the MLL-ALL subtype to topotecan, revealed unique gene expression signatures that distinguished between in vivo responses (Figure 4).

Birinapant Signature BCP-ALL

Topotecan Signature MLL-ALL

4. Discussion and Conclusions

- SMFs provide an accurate and cost-effective platform for preclinical testing of novel agents on an almost clinical trial scale.
- With the elimination of PDX stocks contaminated by thymoma and by using NSG mice instead of the historically used NOD/SCID strain (which has a propensity to develop thymoma), the success rate of preparing single mice from agents previously tested by our group was greatly improved.
- The broad heterogeneity of pediatric ALL to be approximated under prediction over prediction deviation score.

5. References


More Information

*Corresponding author: Richard B. Lock, PhD Email: rock@nci.nih.gov
Presented at: American Society of Hematology (December 2018)
Supported by: U01CA199000 and U01CA199222 from the NCI.
www.ncipptc.org
There are no relationships to disclose.